Overview
Syndex Bio develops the proprietary mcPCR platform, which enables high-fidelity amplification of both DNA methylation patterns and genetic sequences, overcoming limitations of traditional PCR. This technology supports sensitive analysis of methylated DNA in clinical samples, particularly for non-invasive biopsies in early disease detection and cancer monitoring. Based in Cambridge, UK, the company recently raised $15.5M in seed funding to expand R&D and clinical applications.
Frequently asked questions
- What is Syndex Bio's main technology offering?
- Syndex Bio's mcPCR platform preserves DNA methylation patterns during amplification, enabling PCR-like copying of both methylation marks and the four-base genetic code for high-sensitivity analysis.
- What applications does mcPCR support?
- mcPCR supports research and clinical workflows for analyzing methylated DNA in non-invasive and small-sample biopsies, aiding early disease detection, cancer recurrence monitoring, and molecular diagnostics.
- Where is Syndex Bio located and what is their funding status?
- Syndex Bio is based at Melbourn Science Park in Cambridge, UK, and raised an oversubscribed $15.5M seed round led by ARCH Venture Partners to expand the mcPCR platform and R&D.